Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, Double-blind Phase I Study in Healthy Volunteers with IMP761, a LAG-3 Agonist Antibody

Next Previous
Search
Trial Profile

A Placebo-controlled, Double-blind Phase I Study in Healthy Volunteers with IMP761, a LAG-3 Agonist Antibody

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMP 761 (Primary)
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Immutep

    • Most Recent Events

    • 17 Dec 2024 Initial safety data from this study published in the Immutep Limited media release.
    • 17 Oct 2024 According to an Immutep Limited media release, company announces that the first part (Part A, single dose) of this study evaluating IMP761 has been fully recruited and the drug has been administered with no safety issues. And now progressed to the Part B dose escalation phase with single IMP761 dosing planned to move from 0.03 mg/kg up to 0.90 mg/kg.
    • 25 Sep 2024 According to an Immutep Limited media release, company announces, it has received a fund from research and development (R&D) tax incentive payment in cash from the French Government under its Credit d'Impot Recherche scheme (CIR), funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and IMP761.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top